Back to Search
Start Over
The association of CAT-262C/T polymorphism with catalase activity and treatment response in juvenile idiopathic arthritis.
- Source :
-
Rheumatology international [Rheumatol Int] 2019 Mar; Vol. 39 (3), pp. 551-559. Date of Electronic Publication: 2019 Jan 24. - Publication Year :
- 2019
-
Abstract
- Oxidative stress is believed to be of great importance for both the etiology and the persistence of juvenile idiopathic arthritis (JIA). The aim of this study was to investigate the association of -262C/T polymorphism of the catalase (CAT) gene with JIA, as well as to evaluate whether this polymorphism can influence plasma CAT activity and outcome in JIA patients treated with etanercept. A total of 154 subjects (60 JIA patients and 94 healthy volunteers) were screened for CAT-262C/T gene polymorphism using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Plasma CAT activity was determined using the spectrophotometric method according to Goth, prior to and 12 months after anti-TNF (etanercept) therapy. Clinical outcome was assessed using the JIA ACR (American College of Rheumatology) response criteria. The genotype and allele frequency distributions of CAT-262C/T polymorphism in the patients were significantly different from those of the controls (p = 0.014, p = 0.006). The TT genotype (polymorphic homozygous) was associated with a 4.36-fold higher likelihood of having JIA (95% CI 1.545-12.323, p = 0.005) as compared to the CC genotype (wild-type). At month 12 of treatment, JIA patients, carriers of the CC genotype, showed significantly higher plasma CAT activity (p = 0.004) and achieved the JIA ACR 70 response more often (p = 0.003) than the patients, carriers of the CT/TT genotype. This is the first study implying the possible association of CAT-262C/T polymorphism with JIA. The results suggest the potential protective effect of the CC genotype, with regard to CAT activity and treatment outcome.
- Subjects :
- Adolescent
Antirheumatic Agents therapeutic use
Arthritis, Juvenile drug therapy
Child
Drug Therapy, Combination
Etanercept therapeutic use
Female
Gene Frequency
Genetic Predisposition to Disease
Genotype
Humans
Male
Methotrexate therapeutic use
Polymorphism, Single Nucleotide
Treatment Outcome
Tumor Necrosis Factor Inhibitors therapeutic use
Arthritis, Juvenile genetics
Catalase genetics
Subjects
Details
- Language :
- English
- ISSN :
- 1437-160X
- Volume :
- 39
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Rheumatology international
- Publication Type :
- Academic Journal
- Accession number :
- 30680511
- Full Text :
- https://doi.org/10.1007/s00296-019-04246-3